Rankings
▼
Calendar
EBS Q3 2017 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena
EBS
Emergent BioSolutions Inc.
$430M
Q3 2017 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$149M
+4.6% YoY
Gross Profit
$83M
55.7% margin
Operating Income
$48M
32.0% margin
Net Income
$34M
22.5% margin
EPS (Diluted)
$0.68
QoQ Revenue Growth
+48.3%
Cash Flow
Operating Cash Flow
$34M
Free Cash Flow
$21M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$1.0B
Total Liabilities
$360M
Stockholders' Equity
$664M
Cash & Equivalents
$341M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$149M
$143M
+4.6%
Gross Profit
$83M
$76M
+9.2%
Operating Income
$48M
$35M
+34.6%
Net Income
$34M
$21M
+57.2%
← FY 2017
All Quarters
Q4 2017 →